BIONTECH - BUY | USD62.5 vs. USD50 Positive COVID-19 update provides read-through for infectious disease franchise
BIONTECH - BUY | USD62.5 vs. USD45Positive COVID-19 update provides read-through for infectious disease franchise
Positive clinical update on the first COVID-19 vaccine candidate
Immunogenicity data suggest potential protection against COVID
Manageable safety profile largely in-line with expectation and no signs of ADE
BNT162b1 is likely to be one of the leaders among four candidates
Phase IIb/III could begin in July with potential readout in 4Q20
FV increased following strengthened confidence in infectious disease franchise
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.